Valuation: NetraMark Holdings Inc.

Market Cap 7.38Cr 5.24Cr 4.6Cr 4.3Cr 3.94Cr 501.74Cr 7.56Cr 51Cr 20Cr 248.28Cr 20Cr 19Cr 858.3Cr P/E 2026 *
-
P/E 2027 * -
Enterprise Value 7.38Cr 5.24Cr 4.6Cr 4.3Cr 3.94Cr 501.74Cr 7.56Cr 51Cr 20Cr 248.28Cr 20Cr 19Cr 858.3Cr EV / Sales 2026 *
184x
EV / Sales 2027 * -
Free-Float
91.14%
Yield 2026 *
-
Yield 2027 * -
09/07 NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data MT
09/07 NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner CI
29/06 NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company MT
29/06 NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company CI
15/05 NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026 CI
08/05 NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026 CI
04/05 NetraMark Holdings Inc. Announces Executive Changes CI
22/04 NetraMark Holdings Inc. Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs CI
20/04 NetraMark Holdings Inc Announces NetraAI Platform For Clinical Trial Precision Analytics CI
09/04 Netramark Holdings Inc Announces Publication of Peer-Reviewed Article on Psychedelics and Quantum Brain Processes CI
25/03 NetraMark Collaborating With Italian Company To Analyze Phase II Oncology Dataset MT
25/03 Netramark Holdings Inc. and Fondazione Per La Medicina Personalizzata Announce Strategic Research Collaboration CI
25/03 NetraMark Brief: Announcing Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset MT
Manager TitleAgeSince
Chief Executive Officer - 17/02/2022
President - 04/07/2022
Director of Finance/CFO 57 18/07/2022
Director TitleAgeSince
Chairman 40 09/06/2025
Director/Board Member - -
Director/Board Member - 16/06/2022
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-3.77% - - 5.24Cr
-0.71%-1.81%-23.80%+15.42% 2,92200Cr
-0.43%-7.28%-22.09%+590.62% 30TCr
+1.68%-15.05%+151.68%+962.74% 10TCr
-3.47%-3.45%-0.30%+42.06% 9.51TCr
+5.31%+3.69%+75.23%+135.49% 8.93TCr
-2.64%-3.95%-36.94%-17.12% 7.35TCr
+0.89%+1.99%-32.58%+70.07% 6.58TCr
-0.48%+4.45%+8.99%+62.55% 4.63TCr
+1.27%-4.51%-58.56%+28.77% 3.54TCr
Average +1.32%-1.65%+6.85%+210.07% 41.43TCr
Weighted average by Cap. +6.07%-1.57%-16.10%+92.31%

Financials

2026 *2027 *
Net sales 4L 3L 3L 2L 2L 2.73Cr 4L 27.67L 10.82L 1.35Cr 10.68L 10.45L 4.66Cr -
Net income - -
Net Debt - -
Logo NetraMark Holdings Inc.
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.
Employees
-

Quarterly revenue - Rate of surprise